引 致 更 改 給 病 人 的 產 品 資 訊 的 藥 物 不 良 反 應 警 示
|
| |
| Reports of pure red cell aplasia in patients treated with CellCept (mycophenolate mofetil) announced by Health Canada (English only) |
| |
Hoffmann-La Roche Limited (Roche) informs healthcare professionals about reports of pure red cell aplasia in patients treated with CellCept (mycophenolate mofetil) in combination with other immunosuppressive agents. The Canadian product monograph for CellCept has been revised to include this updated safety information.
http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/_2009/cellcept_2_hpc-cps-eng.php
Situation in Hong Kong: CellCept is registered by Roche Hong Kong Limited in HK. The company confirms that the package insert is being updated, and a “Dear Healthcare Professional” letter regarding the above safety information has been issued.
Ends/Friday, June 5, 2009
Issued at HKT 12:30
|
| |
